FDA Shifts Away from Animal Testing—What It Means for the Future of Drug Development (and for Manna Corp)

In a move that marks a new era in medical innovation, the U.S. Food and Drug Administration (FDA) has announced plans to phase out its long-standing requirement for animal testing in certain drug development pathways—including monoclonal antibodies and other advanced therapeutics. This decision opens the door for safer, faster, and more human-relevant alternatives to be used in preclinical research.

At Manna Corporation, this change doesn’t just feel timely—it affirms the very path we’ve been building from day one.

A Better Way Forward

Traditional animal models have long been the gatekeepers of early-stage research. But the reality is: animal biology often fails to accurately predict human response, especially for highly targeted, immune-based treatments. What works in mice doesn’t always translate to humans—and vice versa.

That’s why the FDA’s updated stance is so critical. It embraces new approach methodologies (NAMs)—such as in vitro systems, AI modeling, organ-on-chip platforms, and other non-animal technologies—to ensure safety and efficacy, without the ethical and scientific compromises of outdated models.

Why This Matters for Manna Corp

Our therapeutic peptide immunotherapy is built on precision, not one-size-fits-all biology. From the start, we’ve prioritized a lean, patient-centered development strategy that reflects real-world relevance over abstract models. With this FDA update, we can continue pursuing our fast-track development plan—backed by sound science and now, forward-looking regulatory support.

More importantly, it brings us one step closer to our goal: delivering faster, safer, and more affordable cancer care to patients who need it most.

The Future Is Human-Centered

As we continue through the FDA’s INTERACT program and prepare for clinical trials, this shift will help us streamline approvals and ensure our resources are spent where they matter most: on patient outcomes, not animal test results.

At Manna Corp, we believe drug development should move as fast as the science—and the people—demand. The FDA just brought us all closer to that future.